Boston Scientific (BSX) Stock Forecast & Price Target

Boston Scientific demonstrates a solid financial performance, as evidenced by a gross margin of 70.7%, which reflects a year-over-year improvement driven by an enhanced product mix and exceeded market expectations. The company's diverse product lines, including significant contributions from urology and neuromodulation sales, recorded growth rates of 3.2% and 9.9%, respectively, highlighting strong market demand and successful product launches. Additionally, robust sales growth across Interventional Cardiology & Vascular Therapies, with an increase of 8.3% in the fourth quarter, emphasizes the company's effective strategy in capturing market share and capitalizing on recent acquisitions.

Boston Scientific's operating margin experienced a contraction of 10 basis points year-over-year, primarily due to rising research and development expenses, despite a slight gross margin expansion. The company's organic growth also showed signs of deceleration, dropping to 12.7% in the fourth quarter of 2025 from 15.3% in the third quarter, largely attributed to slowing adoption of FARAPULSE technology amid increasing competition. Furthermore, a bear case scenario suggests revenue growth may remain below 10% with potential share losses in vital markets and operating margin pressures, highlighted by the disappointing performance in the Electrophysiology segment, which contributed to the decline in stock value.